Clinical trials
Relapsed or Refractory Plasma Cell Neoplasms clinical trials
Below are recruiting relapsed or refractory plasma cell neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,686 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07328503RecruitingPhase 2
CD22 CAR T-cells to prevent relapse after CD19 CAR T-cell therapy
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
Bethesda, MarylandAges 3–65 - NCT07480213RecruitingPhase 1/Phase 2
CAR-NK cell therapy for relapsed small cell lung cancer
This trial tests a new type of immunotherapy called dual-target CAR-NK cells for people with small cell lung cancer that has returned or not responded to treatment. The treatment uses your own immune cells, modified in a lab, to better recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07502118RecruitingPhase 2/Phase 3
NexCAR19 for B-cell blood cancers that came back
This trial tests NexCAR19 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma or B-cell acute lymphoblastic leukemia that didn't respond to or came back after other treatments. It aims to see if this therapy can help control the cancer.
AnkaraAges 18 years+ - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07612280RecruitingPhase 1/Phase 2
Testing JBI-802 for blood cell disorders with high platelets
This study tests a new oral medication called JBI-802 to treat rare bone marrow disorders (myeloproliferative and myelodysplastic neoplasms) that cause abnormally high platelet counts. The goal is to evaluate whether the drug is safe and can help lower platelet levels and control disease.
Sydney, New South WalesAges 18 years+ - NCT07759856RecruitingPhase 2
Natural killer cells plus immunotherapy for small cell lung cancer
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT05391490RecruitingPhase 1
Testing donated immune cells for advanced CD19 blood cancers
This early-phase trial tests donated (allogeneic) immune cells engineered to recognize CD19, a target found on many B-cell cancers. It’s designed for people whose CD19+ cancer has come back or didn’t respond after several previous treatments, aiming to shrink tumors and control disease.
LondonAges 16–65 - NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT01189786Recruiting
Stem cell transplant add-on that removes some immune cells
This trial tests a lab-made cell treatment added around an allogeneic stem cell transplant (donor transplant). It tries to improve transplant safety and outcomes by removing certain immune cells from the donor stem cells.
Houston, TexasAges Up to 70 years - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT06569082Recruiting
Stem cell boost for poor graft function
This study tests whether giving extra stem cells from your original donor can help your blood cell counts recover after a transplant. It is for people whose new immune system has not fully engrafted or whose counts are dangerously low.
New York, New YorkAges 18 years+ - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT07744256RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for relapsed small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07197307RecruitingPhase 2
Study of two targeted drugs for relapsed aggressive B-cell lymphoma
This study tests a new combination of two drugs—loncastuximab tesirine (an antibody-drug conjugate) and epcoritamab (a bispecific antibody)—for people whose aggressive B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if the combination is safe and effective.
AachenAges 18 years+ - NCT04169737RecruitingPhase 2
Acalabrutinib and venetoclax for high-risk CLL or SLL
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
Houston, TexasAges 18 years+ - NCT06699771RecruitingPhase 1
Safety study of GCC2005 for NK and T-cell cancers
This trial tests a new drug called GCC2005 for people with certain types of NK or T-cell cancers that have come back or not responded to at least two previous treatments. The goal is to see if it is safe and if it can help shrink tumors.
Seoul, SeoulAges 19–80 - NCT07285668Recruiting
Special donor immune cells after stem cell transplant for high-risk blood cancers
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Madison, WisconsinAges 18–80 - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT04083495RecruitingPhase 2
CAR T treatment for relapsed CD30-positive T-cell lymphoma
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
Chapel Hill, North CarolinaAges 18–99 - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT04332822RecruitingPhase 3
Testing mini-CHOP versus adding polatuzumab for lymphoma
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
AlburyAges 75 years+ - NCT04414475RecruitingPhase 2
Selinexor plus low-dose steroid for hard-to-treat myeloma
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
Pátrai, AchaiaAges 18 years+
Hear when a new Relapsed or Refractory Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory plasma cell neoplasms?
- Yes. Clin2 currently lists 1,686 recruiting relapsed or refractory plasma cell neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory plasma cell neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory plasma cell neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
- Refractory Plasma Cell Myeloma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.